Azithromycin
Based on 45 publication(s) in Google Scholar
Azithromycin is a macrolide antibiotic useful for the treatment of a number of bacterial infections.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.0%
- No. CAS: 83905-01-5
- Fòrmula: C38H72N2O12
- Peso molecular:748.98
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Drug Repurposing Compound Library
HY-L035
-
Macrocyclic Compound Library
HY-L041
-
Antibacterial Compound Library
HY-L049
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Antiparasitic Compound library
HY-L082
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product-like Compound Library
HY-L021L
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
High-Throughput Bioactive Compound Library
HY-L205
-
Cardiotoxic Compound Library
HY-L225
-
Nephrotoxicity Compound Library
HY-L229
-
Classic FDA-Approved Drug Library
HY-L261
Publications Citing Use of MedChemExpress (MCE) Azithromycin
More- Bioact Mater. 2025 Jun 5:52:73-91. [Abstract]
- Acta Pharm Sin B. 2021 Sep;11(9):2850-2858. [Abstract]
- Adv Sci (Weinh). 2020 Jul 21;7(17):2001374. [Abstract]
- Theranostics. 2022 Jan 1;12(3):1187-1203. [Abstract]
- Mol Ther. 2022 Jun 1;30(6):2224-2241. [Abstract]
- Nano Today. 2025 Apr.
- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- Cell Rep Med. 2025 Dec 16;6(12):102478. [Abstract]
- Emerg Microbes Infect. 2024 Dec;13(1):2321981. [Abstract]
- Cell Rep. 2023 Dec 12;42(12):113563. [Abstract]
- Biochem Pharmacol. 2021 Nov:193:114793. [Abstract]
- PLoS Pathog. 2024 Nov 5;20(11):e1012614. [Abstract]
- Invest Ophthalmol Vis Sci. 2021 Feb 1;62(2):33. [Abstract]
- Antimicrob Agents Chemother. 2026 Apr;70(4):e0170625. [Abstract]
- mLife. 2025 Apr 15;4(2):155-168. [Abstract]
- ACS Omega. 2022 Mar 3;7(10):9004-9014. [Abstract]
- iScience. 2022 Jan 5;25(2):103731. [Abstract]
- Microbiol Spectr. 2025 Oct 15:e0122125. [Abstract]
- Microbiol Spectr. 2025 Aug 29:e0059025. [Abstract]
- Microbiol Spectr. 2025 May 19:e0307424. [Abstract]
- ACS Infect Dis. 2024 Apr 12;10(4):1327-1338. [Abstract]
- ACS Chem Biol. 2022 Jan 21;17(1):39-53. [Abstract]
- Viruses. 2020 Jun 10;12(6):628. [Abstract]
- Viruses. 2019 Nov 15;11(11):1064. [Abstract]
- Pathogens. 2026 Feb;15(2):169.
- Pathogens. 2025 Mar 21;14(4):302. [Abstract]
- Pathogens. 2024 Nov 15;13(11):1003. [Abstract]
- Diabetes Metab Syndr Obes. 2025 Aug 5:18:2681-2694. [Abstract]
- Water. 2025 Jun 6.
- Vet Microbiol. 2025 Jun 4:307:110582. [Abstract]
- Immunol Invest. 2025 Jan 9:1-13. [Abstract]
- Immunobiology. 2025 Nov;230(6):153136. [Abstract]
- Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868. [Abstract]
- Rapid Commun Mass Spectrom. 2026 May 30;40(10):e70053. [Abstract]
- COVID. 2021, 1(1), 263-275.
- bioRxiv. 2025 Jun 11.
- Res Sq. 2025 Apr 16.
- bioRxiv. 2024 May 10.
- bioRxiv. 2024 Apr 4.
- Research Square Preprint. 2022 Jun.
- Journal of Pharmaceutical Research International. 33(47B): 274-279, 2021.
- bioRxiv. 2021 Jan 19.
- Universidade de São Paulo. 2020 Sep.
- Charles University. 2020 Jul.
- Patent. US20200101105A1.
Customer Validation & Images
-
RT-PCR
-
WB
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
Ver todos los productos específicos de isoformas Antibiotic
MoreVer todos los productos específicos de isoformas Parasite
More
Actividad biológica
|
Macrolide |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | CC50 |
>600 μM
Compound: Azithromycin
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 32871342] |
| AML12 | CC50 |
>100 μM
Compound: AZI
|
Cytotoxicity against mouse AML12 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against mouse AML12 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38354519] |
| HeLa | IC50 |
160 μg/mL
Compound: Azithromycin
|
Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs
Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs
|
[PMID: 17088489] |
| HeLa | IC50 |
240 μg/mL
Compound: Azithromycin
|
Antiproliferative effect against HeLa cells after 48 hrs
Antiproliferative effect against HeLa cells after 48 hrs
|
[PMID: 17088489] |
| HEp-2 | IC50 |
0.06 μg/mL
Compound: AZM
|
Antibacterial activity against Chlamydia trachomatis L2 infected in HEp-2 cells assessed as inhibition of infectious progeny incubated for 24 hrs by fluorescence microscopy
Antibacterial activity against Chlamydia trachomatis L2 infected in HEp-2 cells assessed as inhibition of infectious progeny incubated for 24 hrs by fluorescence microscopy
|
[PMID: 36696579] |
| HepG2 | IC50 |
>50 μM
Compound: 1
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay
|
[PMID: 22148880] |
| HepG2 | IC50 |
>50 μM
Compound: 6
|
Cytotoxicity against human HepG2 cells after 1 to 4 hrs by MTS assay
Cytotoxicity against human HepG2 cells after 1 to 4 hrs by MTS assay
|
[PMID: 21476508] |
| HepG2 | IC50 |
203 μM
Compound: AZ
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay
|
[PMID: 22321992] |
| HepG2 | IC50 |
203 μM
Compound: AZI
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay
|
[PMID: 22380766] |
| HFF | CC50 |
174 μM
Compound: 3
|
Cytotoxicity against HFF after 48 hrs by MTS assay
Cytotoxicity against HFF after 48 hrs by MTS assay
|
[PMID: 21428405] |
| MG-63 | IC50 |
180 μg/mL
Compound: Azithromycin
|
Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs
Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs
|
[PMID: 17088489] |
| MG-63 | IC50 |
190 μg/mL
Compound: Azithromycin
|
Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs
Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs
|
[PMID: 17088489] |
| Osteoblast | IC50 |
160 μg/mL
Compound: Azithromycin
|
Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs
Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs
|
[PMID: 17088489] |
| Osteoblast | IC50 |
25 μg/mL
Compound: Azithromycin
|
Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs
Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs
|
[PMID: 17088489] |
| THP-1 | EC50 |
0.024 mg/L
Compound: Azithromycin
|
Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 infected in human THP1 cells assessed as decrease of CFU after 24 hrs
Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 infected in human THP1 cells assessed as decrease of CFU after 24 hrs
|
[PMID: 19564365] |
| THP-1 | EC50 |
2.86 mg/L
Compound: Azithromycin
|
Antibacterial activity against methicillin-sensitive Listeria monocytogenes EGD infected in human THP1 cells assessed as decrease of CFU after 24 hrs
Antibacterial activity against methicillin-sensitive Listeria monocytogenes EGD infected in human THP1 cells assessed as decrease of CFU after 24 hrs
|
[PMID: 19564365] |
| THP-1 | IC50 |
>50 μM
Compound: 6
|
Cytotoxicity against human THP1 cells after 1 to 4 hrs by MTS assay
Cytotoxicity against human THP1 cells after 1 to 4 hrs by MTS assay
|
[PMID: 21476508] |
| Vero | CC50 |
>130 μM
Compound: Azithromycin
|
Cytotoxicity against African green monkey Vero cells by MTT assay
Cytotoxicity against African green monkey Vero cells by MTT assay
|
[PMID: 32871342] |
| Vero | CC50 |
>40 μM
Compound: Azithromycin
|
Cytotoxicity against African green monkey Vero cells by Celltiter blue assay
Cytotoxicity against African green monkey Vero cells by Celltiter blue assay
|
[PMID: 32871342] |
| Vero | CC50 |
810 μM
Compound: Azithromycin
|
Antiproliferative against African green monkey Vero cells incubated for 40 hrs by Celltiter assay
Antiproliferative against African green monkey Vero cells incubated for 40 hrs by Celltiter assay
|
[PMID: 32871342] |
| Vero | CC50 |
810 μM
Compound: Azithromycin
|
Antiproliferative against African green monkey Vero cells
Antiproliferative against African green monkey Vero cells
|
[PMID: 32871342] |
| Vero C1008 | CC50 |
>40 μM
Compound: Azithromycin
|
Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm)
Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm)
|
10.1101/2020.04.03.023846 |
| Vero C1008 | EC50 |
2.12 μM
Compound: Azithromycin
|
Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days
Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days
|
10.1101/2020.04.03.023846 |
Azithromycin (2 μM) augments rhinovirus-induced IFNβ expression in primary bronchial epithelial cells from asthmatics, which is associated with over-expression of RIG-I like receptors and repression of viral replication. Knockdown of MDA5, but not knockdown of RIG-I, diminishes azithromycin (2 μM)-enhanced viral-induced IFNβ expression in asthmatic primary bronchial epithelial cells[1]. Azithromycin specifically reduces MMP-9 mRNA and protein levels without affecting NF-κB in endotoxin-challenged monocytic THP-1 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 83905-01-5
-
Appearance Solid
-
Peso molecular 748.98
-
Fòrmula C38H72N2O12
-
Color White to off-white
-
SMILES
C[C@@H]([C@@H]([C@@](C(O[C@@H]([C@@](C)(O)[C@@H]1O)CC)=O)([H])C)O[C@@](O[C@@H](C)[C@@H]2O)([H])C[C@@]2(C)OC)[C@H]([C@](O)(C[C@H](CN([C@@H]1C)C)C)C)O[C@@](O[C@H](C)C[C@@H]3N(C)C)([H])[C@@H]3O
-
Synonyms
CP 62993
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (45)
-
Journal Impact Factor
-
Most Recent
-
Bioact Mater
A dual-targeting strategy to inhibit colorectal cancer liver metastasis via tumor cell ferroptosis and cancer-associated fibroblast reprogramming. [Abstract]2025 Jun 5:52:73-91. PMID: 40530415 -
Acta Pharm Sin B
Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2. [Abstract]2021 Sep;11(9):2850-2858. PMID: 33723501
Azithromycin purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2021 Sep;11(9):2850-2858. [Abstract]
Antiviral activity of tested macrolide antibiotics against HCoV-229E and HCoV-OC43 in vitro.
-
Adv Sci (Weinh)
A Macromolecule Reversing Antibiotic Resistance Phenotype and Repurposing Drugs as Potent Antibiotics. [Abstract]2020 Jul 21;7(17):2001374. PMID: 32995131
Azithromycin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Jul 21;7(17):2001374. [Abstract]
Guanidin-functionalized polycarbonate pEt_20 with a degree of polymerization (DP) of 20 was more effective than colistin sulfate in reducing the MIC and MBC of Azithromycin against both strains.
-
Theranostics
Antibiotic Azithromycin inhibits brown/beige fat functionality and promotes obesity in human and rodents. [Abstract]2022 Jan 1;12(3):1187-1203. PMID: 35154482
Azithromycin purchased from MedChemExpress. Usage Cited in: Theranostics. 2022 Jan 1;12(3):1187-1203. [Abstract]
mRNA levels of thermogenic and mitochondrial gene programs in immortal beige adipocytes treated with or without Azithromycin (AZI) at 5 μM for 24 and 48 h.
Azithromycin purchased from MedChemExpress. Usage Cited in: Theranostics. 2022 Jan 1;12(3):1187-1203. [Abstract]
UCP1 and PGC1α protein levels in immortal beige adipocytes treated with or without Azithromycin (AZI) at 5 μM for 24 and 48 h.
Azithromycin purchased from MedChemExpress. Usage Cited in: Theranostics. 2022 Jan 1;12(3):1187-1203. [Abstract]
Azithromycin treatment induced adiposity and metabolic dysfunctions in mice for HFD. Metabolic performances (relative changes in body weight and body fat) of HFD fed mice treated with or without Azithromycin via drinking water for 12 weeks. (ABX is given throughout the whole process) (ABX: 1.0 g/L; Azithromycin: 50 mg/kg/day) (n = 6 per group).
Azithromycin purchased from MedChemExpress. Usage Cited in: Theranostics. 2022 Jan 1;12(3):1187-1203. [Abstract]
Azithromycin treatment induced adiposity and metabolic dysfunctions in mice for HFD. Metabolic performances (relative glucose tolerance test (GTT) and area under the curve (AUC) analysis) of HFD fed mice treated with or without Azithromycin via drinking water for 12 weeks. (ABX is given throughout the whole process) (ABX: 1.0 g/L; Azithromycin: 50 mg/kg/day) (n = 6 per group).
Azithromycin purchased from MedChemExpress. Usage Cited in: Theranostics. 2022 Jan 1;12(3):1187-1203. [Abstract]
Azithromycin treatment suppressed energy expenditure and thermogenic capacity in mice for HFD. Metabolic performances of HFD fed mice treated with or without Azithromycin via drinking water for 12 weeks (ABX is given throughout the whole process) (ABX: 1.0 g/L; Azithromycin: 50 mg/kg/day) (n = 6). Representative images of H&E staining of fat tissues.
-
Mol Ther
Nucleic acid aptamer controls mycoplasma infection for inhibiting the malignancy of esophageal squamous cell carcinoma. [Abstract]2022 Jun 1;30(6):2224-2241. PMID: 35189346 -
-
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
Cell Rep Med
Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. [Abstract]2025 Dec 16;6(12):102478. PMID: 41406946 -
Emerg Microbes Infect
AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria. [Abstract]2024 Dec;13(1):2321981. PMID: 38422452 -
Cell Rep
Intratumor Mycoplasma promotes the initiation and progression of hepatocellular carcinoma. [Abstract]2023 Dec 12;42(12):113563. PMID: 38088929 -
Biochem Pharmacol
Azithromycin modulates Teff/Treg balance in retinal inflammation via the mTOR signaling pathway. [Abstract]2021 Nov:193:114793. PMID: 34600916 -
PLoS Pathog
2024 Nov 5;20(11):e1012614. PMID: 39499730 -
Invest Ophthalmol Vis Sci
Hedgehog Signaling Pathway Regulates the Proliferation and Differentiation of Rat Meibomian Gland Epithelial Cells. [Abstract]2021 Feb 1;62(2):33. PMID: 33616621 -
Antimicrob Agents Chemother
Stepwise evolution and clonal enrichment of gepotidacin resistance in Neisseria gonorrhoeae. [Abstract]2026 Apr;70(4):e0170625. PMID: 41810969 -
mLife
Identification of a phenyl ester covalent inhibitor of caseinolytic protease and analysis of the ClpP1P2 inhibition in mycobacteria. [Abstract]2025 Apr 15;4(2):155-168. PMID: 40313980 -
ACS Omega
Lapatinib Acts against Biofilm Formation and the Hemolytic Activity of Staphylococcus aureus. [Abstract]2022 Mar 3;7(10):9004-9014. PMID: 35309438 -
iScience
2022 Jan 5;25(2):103731. PMID: 35098100 -
Microbiol Spectr
Montelukast treats Streptococcus pneumoniae-induced sepsis via antibacterial and anti-inflammatory activities. [Abstract]2025 Oct 15:e0122125. PMID: 41090944 -
Microbiol Spectr
2025 Aug 29:e0059025. PMID: 40879403 -
Microbiol Spectr
Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan. [Abstract]2025 May 19:e0307424. PMID: 40387379 -
ACS Infect Dis
Lusutrombopag as a Repurposing Drug in Combination with Aminoglycosides against Vancomycin-Resistant Enterococcus. [Abstract]2024 Apr 12;10(4):1327-1338. PMID: 38567846 -
ACS Chem Biol
Investigate Natural Product Indolmycin and the Synthetically Improved Analogue Toward Antimycobacterial Agents. [Abstract]2022 Jan 21;17(1):39-53. PMID: 34908399 -
Viruses
Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). [Abstract]2020 Jun 10;12(6):628. PMID: 32532085 -
Viruses
Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator. [Abstract]2019 Nov 15;11(11):1064. PMID: 31731598 -
-
Pathogens
N-Acetylcysteine as a Host-Directed Therapy Against Clarithromycin-Resistant Mycobacterium abscessus. [Abstract]2025 Mar 21;14(4):302. PMID: 40333083 -
Pathogens
Mycoplasma bovis Invades Non-Phagocytic Cells by Clathrin-Dependent Endocytic Pathways and Escapes from Phagocytic Vesicles. [Abstract]2024 Nov 15;13(11):1003. PMID: 39599557 -
Diabetes Metab Syndr Obes
A Network Pharmacology-Based Investigation into the Mechanism of Quercetin Combined with Rosuvastatin in Delaying Diabetic Nephropathy via Inhibiting NRK-52E Cell Ferroptosis. [Abstract]2025 Aug 5:18:2681-2694. PMID: 40785752 -
-
Vet Microbiol
Emergence of multidrug resistance and genomic analysis of azithromycin-resistant non-typhoidal Salmonella from diverse sources in China, 2006-2018. [Abstract]2025 Jun 4:307:110582. PMID: 40482360 -
Immunol Invest
The Mechanism of Baicalin in the Treatment of Mycoplasma Pneumoniae Pneumonia by Regulating NLRP3/Caspase-1 Signaling Pathway. [Abstract]2025 Jan 9:1-13. PMID: 39781905 -
Immunobiology
Dual-phase study of CD4+CXCR4+ T cells in Mycoplasma pneumoniae pneumonia: clinical correlations in children and therapeutic exploration with tofacitinib in mice. [Abstract]2025 Nov;230(6):153136. PMID: 41192098 -
Biochem Biophys Res Commun
Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities. [Abstract]2020 Feb 19;522(4):862-868. PMID: 31806372 -
Rapid Commun Mass Spectrom
Sensitive Detection of Salmonella Susceptibility to Ceftriaxone and Azithromycin Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. [Abstract]2026 May 30;40(10):e70053. PMID: 41704149 -
-
-
-
-
-
-
-
-
-
-
Solvente y solubilidad
DMSO : ≥ 100 mg/mL (133.51 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.34 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (3.34 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
THP-1 cells (106 cells in 1 mL RPMI medium, without antibiotics, growth factors or serum) are seeded in each well of 24-well plates and allowed to settle for 1 hour. Next, 50 μL of the test compound is added followed by 50 μL of LPS (final concentration of 10 μg/mL). After 24h (37°C and 5% CO2) the supernatants and cell pellets are collected (1200 rpm, 5 min). THP-1 cell viability is tested using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). MTT is dissolved at 2 mg/mL in PBS and aliquots are stored at -20°C. The MTT assay is performed according to the suppliers instructions. Absorbance of MTT converted into formazan is measured at a wavelength of 570 nm with background subtraction at 630 nm.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Menzel M, et al. Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget. 2017 Mar 18. [Content Brief]
[2]. Vandooren J, et al. Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study. PLoS One. 2017 Apr 3;12(4):e0174853. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.3351 mL | 6.6757 mL | 13.3515 mL | 33.3787 mL |
| 5 mM | 0.2670 mL | 1.3351 mL | 2.6703 mL | 6.6757 mL | |
| 10 mM | 0.1335 mL | 0.6676 mL | 1.3351 mL | 3.3379 mL | |
| 15 mM | 0.0890 mL | 0.4450 mL | 0.8901 mL | 2.2252 mL | |
| 20 mM | 0.0668 mL | 0.3338 mL | 0.6676 mL | 1.6689 mL | |
| 25 mM | 0.0534 mL | 0.2670 mL | 0.5341 mL | 1.3351 mL | |
| 30 mM | 0.0445 mL | 0.2225 mL | 0.4450 mL | 1.1126 mL | |
| 40 mM | 0.0334 mL | 0.1669 mL | 0.3338 mL | 0.8345 mL | |
| 50 mM | 0.0267 mL | 0.1335 mL | 0.2670 mL | 0.6676 mL | |
| 60 mM | 0.0223 mL | 0.1113 mL | 0.2225 mL | 0.5563 mL | |
| 80 mM | 0.0167 mL | 0.0834 mL | 0.1669 mL | 0.4172 mL | |
| 100 mM | 0.0134 mL | 0.0668 mL | 0.1335 mL | 0.3338 mL |
Powered by Bioz